{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"ENSC","limit":50},"count":50,"signals":[{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"614-MPAR was granted Breakthrough Therapy designation by the FDA in January 2024. A second study, PF614-MPAR-102, designed to evaluate the overdose protection across a range of dosages, initiated enrollment of subjects in December 2024 and is continuing enrollment. Our pipeline has been developed over the course of more than twenty years of research and investment and includes three clinical-stage pr","filed_date":"2026-03-30","accession":"0001493152-26-013633","full_text":"https://origin.rootz.global/static/filing/0001493152-26-013633.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":43,"context":"r product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following regulatory approval, if obtained. | | |  |  |  | | |  |  |  Even if any of our product candidates receives regulatory approval, we may fail to achieve the degree of market acceptance neces","filed_date":"2026-03-30","accession":"0001493152-26-013633","full_text":"https://origin.rootz.global/static/filing/0001493152-26-013633.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":43,"context":"r product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following regulatory approval, if obtained. | | |  |  |  | | |  |  |  Even if any of our product candidates receives regulatory approval, we may fail to achieve the degree of market acceptance neces","filed_date":"2025-03-10","accession":"0001493152-25-009703","full_text":"https://origin.rootz.global/static/filing/0001493152-25-009703.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":26,"context":"ee Risk Factors Risks Related to this Offering and Our SecuritiesIf we are unable to maintain compliance with the listing standards of Nasdaq, our common stock may become delisted, which could have a material adverse effect on our ability to raise funding, which could negatively impact our business, capital and financial condition, which addresses our receipt of a Delisting Letter from The Nasdaq Capital Market. | | |","filed_date":"2024-03-26","accession":"0001493152-24-011321","full_text":"https://origin.rootz.global/static/filing/0001493152-24-011321.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":13,"context":"he 2023 Notes and issued 1.3 million shares of common stock for $2.1 million upon exercise of warrants issued in conjunction with the 2023 Notes, as discussed in Note 7. In February 2024, the Company entered into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 3,601,752 shares of common stock of the Company originally issued in May 2023, having an exercise price o","filed_date":"2024-03-26","accession":"0001493152-24-011321","full_text":"https://origin.rootz.global/static/filing/0001493152-24-011321.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":43,"context":"r product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following regulatory approval, if obtained. | | |  |  |  | | |  |  |  Even if any of our product candidates receives regulatory approval, we may fail to achieve the degree of market acceptance neces","filed_date":"2024-03-15","accession":"0001493152-24-009993","full_text":"https://origin.rootz.global/static/filing/0001493152-24-009993.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":15,"context":"he 2023 Notes and issued 1.3 million shares of common stock for $2.1 million upon exercise of warrants issued in conjunction with the 2023 Notes, as discussed in Note 7. In February 2024, the Company entered into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 3,601,752 shares of common stock of the Company originally issued in May 2023, having an exercise price o","filed_date":"2024-03-15","accession":"0001493152-24-009993","full_text":"https://origin.rootz.global/static/filing/0001493152-24-009993.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":27,"context":"ee Risk Factors Risks Related to this Offering and Our SecuritiesIf we are unable to maintain compliance with the listing standards of Nasdaq, our common stock may become delisted, which could have a material adverse effect on our ability to raise funding, which could negatively impact our business, capital and financial condition, which addresses our receipt of a Delisting Letter from The Nasdaq Capital Market. | | |","filed_date":"2024-01-17","accession":"0001493152-24-002548","full_text":"https://origin.rootz.global/static/filing/0001493152-24-002548.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":17,"context":"tion to we, our, us, the Company or Ensysce generally refer to Ensysce and its consolidated subsidiaries.* This section discusses the material components of the executive compensation program for our named executive officers. Our named executive officers, consisting of our principal executive officer and the next two most highly compensated executive officers, for the year ended December 31, 2022, were: |  |  |  D. Lynn","filed_date":"2024-01-17","accession":"0001493152-24-002548","full_text":"https://origin.rootz.global/static/filing/0001493152-24-002548.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":25,"context":"r product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following regulatory approval, if obtained. | | |  |  |  | | |  |  |  Even if any of our product candidates receives regulatory approval, we may fail to achieve the degree of market acceptance neces","filed_date":"2023-03-30","accession":"0001493152-23-009844","full_text":"https://origin.rootz.global/static/filing/0001493152-23-009844.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":25,"context":"r product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following regulatory approval, if obtained. | | |  |  |  Even if any of our product candidates receives regulatory approval, we may fail to achieve the degree of market acceptance necessary for comm","filed_date":"2022-03-31","accession":"0001493152-22-008438","full_text":"https://origin.rootz.global/static/filing/0001493152-22-008438.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":18,"context":"tion to we, our, us, the Company or Ensysce generally refer to Ensysce and its consolidated subsidiaries.* This section discusses the material components of the executive compensation program for our named executive officers. Our named executive officers, consisting of our principal executive officer and the next two most highly compensated executive officers, for the year ended December 31, 2020, were: |  |  |  D. Lynn","filed_date":"2021-12-17","accession":"0001493152-21-031828","full_text":"https://origin.rootz.global/static/filing/0001493152-21-031828.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":30,"context":"**NOTE 6 - COMMITMENTS AND CONTINGENCIES** **** **Litigation** As of September 30, 2021 and December 31, 2020, there were no pending legal proceedings against the Company that are expected to have a material adverse effect on cash flows, financial condition or results of operations. From time to time, the Company could become involved in disputes and various litigation matters that arise in the normal course of busines","filed_date":"2021-11-15","accession":"0001493152-21-028735","full_text":"https://origin.rootz.global/static/filing/0001493152-21-028735.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":30,"context":"| | | **NOTE 6 - COMMITMENTS AND CONTINGENCIES** **** **Litigation** As of June 30, 2021 and December 31, 2020, there were no pending legal proceedings against the Company that are expected to have a material adverse effect on cash flows, financial condition or results of operations. From time to time, the Company could become involved in disputes and various litigation matters that arise in the normal course of busines","filed_date":"2021-08-16","accession":"0001493152-21-019916","full_text":"https://origin.rootz.global/static/filing/0001493152-21-019916.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":10,"context":"our Business Combination with only a single entity, our lack of diversification may: |  |  |  subject us to negative economic, competitive and regulatory developments, any or all of which may have a substantial adverse impact on the particular industry in which we operate after our Business Combination; and | | |  |  |  | | |  |  |  cause us to depend on the marketing and sale of a single product or limited number of prod","filed_date":"2021-06-08","accession":"0001493152-21-013767","full_text":"https://origin.rootz.global/static/filing/0001493152-21-013767.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":7,"context":"our Business Combination with only a single entity, our lack of diversification may: |  |  |  subject us to negative economic, competitive and regulatory developments, any or all of which may have a substantial adverse impact on the particular industry in which we operate after our Business Combination; and | | |  |  |  | | |  |  |  cause us to depend on the marketing and sale of a single product or limited number of prod","filed_date":"2021-03-15","accession":"0001213900-21-015361","full_text":"https://origin.rootz.global/static/filing/0001213900-21-015361.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":41,"context":"r purported to be owned, or licensed, by the Company or any of its Subsidiaries, or currently used or held for use in the Business whether registered or unregistered or domestic or foreign. 4 Company Material Adverse Effect means any event, state of facts, condition, change, development, circumstance, occurrence or effect that has had, or would reasonably be expected to have, individually or in the aggregate, a material","filed_date":"2021-02-02","accession":"0001213900-21-005974","full_text":"https://origin.rootz.global/static/filing/0001213900-21-005974.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":8,"context":"our Business Combination with only a single entity, our lack of diversification may: |  |  |  subject us to negative economic, competitive and regulatory developments, any or all of which may have a substantial adverse impact on the particular industry in which we operate after our Business Combination; and | | |  |  |  | | |  |  |  cause us to depend on the marketing and sale of a single product or limited number of prod","filed_date":"2020-03-10","accession":"0001213900-20-005867","full_text":"https://origin.rootz.global/static/filing/0001213900-20-005867.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":44,"context":"equirement imposed by a Governmental Authority in connection with granting a Permit, Regulatory Approval or other consent or approval that would or would reasonably be expected to result in a Company Material Adverse Effect pursuant to subclause (a) of the definition of Company Material Adverse Effect. Business Combination has the meaning specified in the Recitals. Business Combination Deadline means the date by which L","filed_date":"2019-12-31","accession":"0001213900-19-027232","full_text":"https://origin.rootz.global/static/filing/0001213900-19-027232.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":16,"context":"City, Quebec Toronto, Ontario Ottawa, Ontario Winnipeg, Manitoba Regina, Saskatchewan Victoria, British Columbia Vancouver, British Columbia Edmonton, Alberta Calgary, Alberta or in any other place selected by the directors of the Corporation in accordance with applicable corporate legislation. |  | 3. | For the purpose of these articles: | | |  | (a) | a Person is an associate of another Person if: | | |  | (i) | one","filed_date":"2019-12-31","accession":"0001213900-19-027232","full_text":"https://origin.rootz.global/static/filing/0001213900-19-027232.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":8,"context":"our Business Combination with only a single entity, our lack of diversification may: |  |  |  subject us to negative economic, competitive and regulatory developments, any or all of which may have a substantial adverse impact on the particular industry in which we operate after our Business Combination; and | | |  |  |  cause us to depend on the marketing and sale of a single product or limited number of products or servi","filed_date":"2019-03-11","accession":"0001615774-19-003912","full_text":"https://origin.rootz.global/static/filing/0001615774-19-003912.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":8,"context":"ng our Business Combination with only a single entity, our lack of diversification may: |  | | subject us to negative economic, competitive and regulatory developments, any or all of which may have a substantial adverse impact on the particular industry in which we operate after our Business Combination; and | | 10  |  | | cause us to depend on the marketing and sale of a single product or limited number of products or ser","filed_date":"2018-03-09","accession":"0001615774-18-001769","full_text":"https://origin.rootz.global/static/filing/0001615774-18-001769.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":96,"match_count":12,"context":"warded to the Company by NIH through NIDA in September 2018 | | |  Nasdaq |  |  The Nasdaq Stock Market LLC | | |  NCE |  |  New Chemical Entity | | |  NDA |  |  New Drug Application | | |  NEO |  |  Named Executive Officer | | |  NIDA |  |  National Institute of Drug Abuse | | |  NIH |  |  National Institutes of Health | | |  NME |  |  New molecular entity | | |  Orange Book |  |  FDAs publication Approved Drug Product","filed_date":"2026-03-30","accession":"0001493152-26-013633","full_text":"https://origin.rootz.global/static/filing/0001493152-26-013633.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":96,"match_count":12,"context":"two reverse stock splits and several share issuances, that a substantial number of the options we have issued are significantly out of the money and the recommendations by the Companys CEO for other named executive officers. In view of the foregoing and for the reasons described below, on November 20, 2025, the Board approved the Plan Amendment, provided that the Plan Amendment is subject to approval by our stockholder","filed_date":"2025-12-02","accession":"0001493152-25-025696","full_text":"https://origin.rootz.global/static/filing/0001493152-25-025696.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":96,"match_count":12,"context":"warded to the Company by NIH through NIDA in September 2018 | | |  Nasdaq |  |  The Nasdaq Stock Market LLC | | |  NCE |  |  New Chemical Entity | | |  NDA |  |  New Drug Application | | |  NEO |  |  Named Executive Officer | | |  NIDA |  |  National Institute of Drug Abuse | | |  NIH |  |  National Institutes of Health | | |  NME |  |  New molecular entity | | |  Orange Book |  |  FDAs publication Approved Drug Product","filed_date":"2025-03-10","accession":"0001493152-25-009703","full_text":"https://origin.rootz.global/static/filing/0001493152-25-009703.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"ity to successfully develop, obtain regulatory approval for and commercialize one or more of our product candidates. A Phase 1b study of PF614 was initiated in 2021. Part A of the study completed enrollment in December 2021 and Part B was completed mid-year 2022. Two Human Abuse Potential clinical studies were completed in 2023. A Phase 1 trial was also initiated for PF614-MPAR in December 2021 and t","filed_date":"2024-03-26","accession":"0001493152-24-011321","full_text":"https://origin.rootz.global/static/filing/0001493152-24-011321.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"ity to successfully develop, obtain regulatory approval for and commercialize one or more of our product candidates. A Phase 1b study of PF614 was initiated in 2021. Part A of the study completed enrollment in December 2021 and Part B was completed mid-year 2022. Two Human Abuse Potential clinical studies were completed in 2023. A Phase 1 trial was also initiated for PF614-MPAR in December 2021 and t","filed_date":"2024-01-17","accession":"0001493152-24-002548","full_text":"https://origin.rootz.global/static/filing/0001493152-24-002548.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":96,"match_count":12,"context":"th respect to their duties to Inspired. Our officers and directors have agreed not to participate in the formation of, or become an officer or director of, any other blank check company until we have entered into a definitive agreement regarding our Business Combination or we have failed to complete our Business Combination within the required timeframe. *Business Combination* The Nasdaq rules require that our Business Combination","filed_date":"2021-06-08","accession":"0001493152-21-013767","full_text":"https://origin.rootz.global/static/filing/0001493152-21-013767.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":96,"match_count":12,"context":"th respect to their duties to Inspired. Our officers and directors have agreed not to participate in the formation of, or become an officer or director of, any other blank check company until we have entered into a definitive agreement regarding our Business Combination or we have failed to complete our Business Combination within the required timeframe. *Business Combination* The Nasdaq rules require that our Business Combination","filed_date":"2021-03-15","accession":"0001213900-21-015361","full_text":"https://origin.rootz.global/static/filing/0001213900-21-015361.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"614-MPAR was granted Breakthrough Therapy designation by the FDA in January 2024. A second study, PF614-MPAR-102, designed to evaluate the overdose protection across a range of dosages, initiated enrollment of subjects in December 2024 and is continuing enrollment. Our pipeline has been developed over the course of 15 years of research and investment and includes three clinical-stage product candidat","filed_date":"2025-03-10","accession":"0001493152-25-009703","full_text":"https://origin.rootz.global/static/filing/0001493152-25-009703.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"2022. Part B of the study to test the overdose protection of the selected PF614-MPAR 25 mg formulation by administering an escalating number of dose units to a group of healthy subjects completed enrollment in March 2023. The PK data from Part B successfully showed that PF614-MPAR 25 mg administered at a prescribed dose of one or two dose units (capsules) provided oxycodone in an equivalent manner to","filed_date":"2024-03-15","accession":"0001493152-24-009993","full_text":"https://origin.rootz.global/static/filing/0001493152-24-009993.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":88,"match_count":11,"context":"tise qualifies her to serve on our Board. There are no family relationships among any of our directors or executive officers. | 5 | | **Required Vote of Stockholders** A nominee for director shall be elected to the Board of Directors if the votes properly cast FOR such nominees election exceed the votes properly cast AGAINST such nominee election (with ABSTENTIONS and broker non-votes not counted as votes cast either FOR or AGAI","filed_date":"2023-07-14","accession":"0001493152-23-024520","full_text":"https://origin.rootz.global/static/filing/0001493152-23-024520.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":80,"match_count":10,"context":"th respect to their duties to Inspired. Our officers and directors have agreed not to participate in the formation of, or become an officer or director of, any other blank check company until we have entered into a definitive agreement regarding our Business Combination or we have failed to complete our Business Combination within the required timeframe. Business Combination The Nasdaq rules require that our Business Combination mu","filed_date":"2018-03-09","accession":"0001615774-18-001769","full_text":"https://origin.rootz.global/static/filing/0001615774-18-001769.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"ealthy subjects. **Next Steps** **** We initiated additional clinical studies with PF614 in the fourth quarter of 2021. A multi ascending dose study with a bioequivalence arm, PF614-102 concluded enrollment, with data anticipated in the second quarter of 2022. In 2022, two human abuse liability studies will be initiated to understand the tendency for drug abusers to like the effects achieved from tak","filed_date":"2022-03-31","accession":"0001493152-22-008438","full_text":"https://origin.rootz.global/static/filing/0001493152-22-008438.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"nt activities; | | |  |  |  | | |  |  |  establishing an appropriate safety and efficacy profile with investigational new drug (IND) enabling studies; | | |  |  |  | | |  |  |  successful patient enrollment in and the initiation and completion of clinical trials; | | |  |  |  | | |  |  |  the timing, receipt and terms of any marketing approvals from applicable regulatory authorities including the FDA","filed_date":"2021-11-15","accession":"0001493152-21-028735","full_text":"https://origin.rootz.global/static/filing/0001493152-21-028735.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"nt activities; | | |  |  |  | | |  |  |  establishing an appropriate safety and efficacy profile with investigational new drug (IND) enabling studies; | | |  |  |  | | |  |  |  successful patient enrollment in and the initiation and completion of clinical trials; | | |  |  |  | | |  |  |  the timing, receipt and terms of any marketing approvals from applicable regulatory authorities including the FDA","filed_date":"2021-08-16","accession":"0001493152-21-019916","full_text":"https://origin.rootz.global/static/filing/0001493152-21-019916.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":72,"match_count":9,"context":"th respect to their duties to Inspired. Our officers and directors have agreed not to participate in the formation of, or become an officer or director of, any other blank check company until we have entered into a definitive agreement regarding our Business Combination or we have failed to complete our Business Combination within the required timeframe. Business Combination The Nasdaq rules require that our Business Combination mu","filed_date":"2020-03-10","accession":"0001213900-20-005867","full_text":"https://origin.rootz.global/static/filing/0001213900-20-005867.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":72,"match_count":9,"context":"th respect to their duties to Inspired. Our officers and directors have agreed not to participate in the formation of, or become an officer or director of, any other blank check company until we have entered into a definitive agreement regarding our Business Combination or we have failed to complete our Business Combination within the required timeframe. Business Combination The Nasdaq rules require that our Business Combination mu","filed_date":"2019-03-11","accession":"0001615774-19-003912","full_text":"https://origin.rootz.global/static/filing/0001615774-19-003912.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":64,"match_count":8,"context":"ity to successfully develop, obtain regulatory approval for and commercialize one or more of our product candidates. A Phase 1b study of PF614 was initiated in 2021. Part A of the study completed enrollment in December 2021 and Part B was completed mid-year 2022. A Phase 1 trial was also initiated for PF614-MPAR in December 2021 and the clinical portion of Part A of that trial was completed in Decemb","filed_date":"2023-03-30","accession":"0001493152-23-009844","full_text":"https://origin.rootz.global/static/filing/0001493152-23-009844.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":64,"match_count":8,"context":"ub and Former Ensysce, dated January 31, 2021, providing for, among other things, and subject to terms and conditions therein, the business combination between LACQ and Former Ensysce pursuant to the merger of Merger Sub with and into Former Ensysce, with Former Ensysce continuing as the surviving entity and as a wholly-owned subsidiary of LACQ | | |  CARA |  |  Comprehensive Addiction and Recovery Act | |","filed_date":"2023-03-30","accession":"0001493152-23-009844","full_text":"https://origin.rootz.global/static/filing/0001493152-23-009844.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":64,"match_count":8,"context":"the GEM Agreement | | |  DSCSA |  |  Title II of the Federal Drug Quality and Security Act of 2013, known as the Drug Supply Chain Security Act | | |  EB |  |  Ensysce Biosciences, Inc. prior to its merger with Signature Acquisition Corp. pursuant to the EB-ST Agreement. | | |  EB-ST Agreement |  |  Agreement and Plan of Merger, dated as of December 28, 2015, by and among Signature, SAQ, and EB | | |  EMA |","filed_date":"2022-03-31","accession":"0001493152-22-008438","full_text":"https://origin.rootz.global/static/filing/0001493152-22-008438.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":64,"match_count":8,"context":"ors and director nominees have agreed, pursuant to a written letter agreement, not to participate in the formation of, or become an officer or director of, any other blank check company until we have entered into a definitive agreement regarding our business combination or we have failed to complete our business combination. Our management team is not currently involved in any other blank check offering. 24 **Executive Compensation","filed_date":"2019-10-28","accession":"0001213900-19-021284","full_text":"https://origin.rootz.global/static/filing/0001213900-19-021284.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":56,"match_count":7,"context":"rsity of California-San Francisco. | 18 | | | | | There are no family relationships among any of our directors or executive officers. **Required Vote of Stockholders** A nominee for director shall be elected to the Board of Directors if the votes properly cast FOR such nominees election exceed the votes properly cast AGAINST such nominee election (with ABSTENTIONS and broker non-votes not counted as votes cast either FOR or AGAI","filed_date":"2024-10-18","accession":"0001493152-24-041470","full_text":"https://origin.rootz.global/static/filing/0001493152-24-041470.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":56,"match_count":7,"context":"lder approval of the grant (this type of option grant is described herein as a Conditional Grant), with 25% of the option vesting on February 11, 2022, and the remainder vesting in equal monthly installments thereafter. The option has an exercise price equal to $3.13, which was greater than the fair market value of our common stock upon grant. Pursuant to an employment agreement with our Chief Scient","filed_date":"2021-12-17","accession":"0001493152-21-031828","full_text":"https://origin.rootz.global/static/filing/0001493152-21-031828.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":56,"match_count":7,"context":"nd appeal processes. The Company believes completion of the merger will enable it to evidence Nasdaq listing compliance by June 30, 2021; however, there can be no assurance that the Companys proposed merger with Ensysce will be completed or that the Companys securities will trade on Nasdaq upon completion of the merger. In addition, and prior to the issuance of Suspension Notice, on May 25, 2021, the Company","filed_date":"2021-06-08","accession":"0001493152-21-013768","full_text":"https://origin.rootz.global/static/filing/0001493152-21-013768.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":56,"match_count":7,"context":"or Approval of the Director Proposal** ** ** Directors are elected by a plurality of the votes cast at the Special Meeting. The two nominees receiving the highest number of affirmative votes shall be elected as directors. You may withhold votes from any nominee. **Recommendation of the Board** ** ** **The Board unanimously recommends stockholders vote FOR the election to the Board of each of the director nominees.**","filed_date":"2020-11-03","accession":"0001213900-20-034831","full_text":"https://origin.rootz.global/static/filing/0001213900-20-034831.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":49,"match_count":3,"context":"elivery of goods or the performance of services. **Litigation** As of September 30, 2023 and December 31, 2022, there were no pending legal proceedings against the Company that are expected to have a material adverse effect on cash flows, financial condition or results of operations. From time to time, the Company could become involved in disputes and various litigation matters that arise in the normal course of busines","filed_date":"2023-11-09","accession":"0001493152-23-040091","full_text":"https://origin.rootz.global/static/filing/0001493152-23-040091.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":48,"match_count":6,"context":"cation agreement (an Indemnification Agreement) with each of our directors and executive officers. Each Indemnification Agreement requires us to indemnify and hold harmless the applicable director or named executive officer to the fullest extent authorized by the laws of the State of Delaware. Each Indemnification Agreement also requires us, subject to specific terms and conditions, to advance expenses to the director o","filed_date":"2021-07-07","accession":"0001493152-21-016378","full_text":"https://origin.rootz.global/static/filing/0001493152-21-016378.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":48,"match_count":6,"context":"ors and director nominees have agreed, pursuant to a written letter agreement, not to participate in the formation of, or become an officer or director of, any other blank check company until we have entered into a definitive agreement regarding our Business Combination or we have failed to complete our Business Combination within 24 months after the closing of our IPO. Our management team is not currently involved in any other bla","filed_date":"2018-11-14","accession":"0001615774-18-012737","full_text":"https://origin.rootz.global/static/filing/0001615774-18-012737.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ENSC","company":"Ensysce Biosciences, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":45,"match_count":5,"context":"ub and Former Ensysce, dated January 31, 2021, providing for, among other things, and subject to terms and conditions therein, the business combination between LACQ and Former Ensysce pursuant to the merger of Merger Sub with and into Former Ensysce, with Former Ensysce continuing as the surviving entity and as a wholly-owned subsidiary of LACQ | | |  CMOs |  |  Contract manufacturing organizations | | |","filed_date":"2023-11-09","accession":"0001493152-23-040091","full_text":"https://origin.rootz.global/static/filing/0001493152-23-040091.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"063a53bb7e7be11aab2677530008c019f4453033868e55f4814546fcfc35e29e","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"47bf37e8c081e1138f2e11619084103654ea88f9438e4d652cfca4bdca73e9f7","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":39,"hourly_limit":500,"remaining":461,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}